CDKN2A and lung carcinoma: We found that p16 expression was positive in 24% (12/50) of lung cancer patients and all (12/12) of the p16-positive patients were HPV-positive while none of the HPV-negative patients showed p16 expression and 30.8% (12/39) of the HPV-positive patients were p16-positive.